

REMARKS

The amendments to the claims are made to delete multiple dependence and to correct obvious typographical errors and eliminate superfluous language. It is respectfully submitted that no new subject matter has been added and entry of the amendment is respectfully requested.

The Commissioner is hereby authorized to charge any fees associated with this response or credit any overpayment to Deposit Account No. 13-3402.

Respectfully submitted,



Brion P. Heaney Reg. No. 32,542
Attorney/Agent for Applicant(s)

MILLEN, WHITE, ZELANO
& BRANIGAN, P.C.
Arlington Courthouse Plaza 1, Suite 1400
2200 Clarendon Boulevard
Arlington, Virginia 22201
Telephone: (703) 243-6333
Facsimile: (703) 243-6410

Attorney Docket No.: PHARMA-123

Date: January 16, 2002

VERSION WITH MARKINGS TO SHOW CHANGES MADE

The claims have been amended as follows:

29. (Amended) A method according to ~~any one of claims~~ claim 1-28, wherein said cancer is prostate cancer, colon cancer, lung cancer, melanoma, ovarian cancer, renal cancer, breast cancer, lymphoma, pancreatic cancer or bladder cancer.

30. (Amended) A method according to ~~any one of claims~~ claim 3-28, wherein said cancer is leukemia.

31. (Amended) A method according to ~~any one of claims~~ claim 1-28, wherein at least one of R₁, R₃, or R₄ is piperazinyl, piperidinyl, morpholinyl, pyrrolidinyl, adamantyl or quinuclidinyl.

32. (Amended) A method according to ~~any one of claims~~ claim 1-28, wherein at least one of R₁, R₃ or R₄ is acetyl, propionyl, butyryl, valeryl, caproic, caprylic, capric, lauric, myristic, palmitic, stearic, oleic, linoleic, or linolenic.

33. (Amended) A method according to ~~any one of claims~~ claim 1-28, wherein at least one of R₁, R₃ or R₄ is cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, naphthyl or biphenyl.

34. (Amended) A method according to ~~any one of claims~~ claim 1-28, wherein at least one of R₁, R₃ or R₄ contains a heterocyclic group selected from the following group:
furyl, thiophenyl, pyrrolyl, imidazolyl, pyrazoyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyridyl, pyrimidinyl, triazolyl, tetrazolyl, oxadiazolyl ~~exadiazolyl~~, thiadiazolyl, thiopyranyl, pyrazinyl, benzofuryl, benzothiophenyl, indolyl, benzimidazolyl, benzopyrazolyl, benzoxazolyl, benzisoxazolyl, benzothiazolyl-~~benzothieozoly~~, benzisothiazolyl,

benzoxadiazolyl, quinolinyl, isoquinolinyl, carbazolyl, acridinyl, cinnolinyl and quinazolinyl.



35. (Amended) A method according to ~~any one of claims~~ claim 1-28, wherein said compound is administered at least daily for a period of 2 to 10 days every 2 to 5 weeks.


36. (Amended) A method according to ~~any one of claims~~ claim 1-28, wherein said compound is administered at least daily for a period of 2 to 10 days every 3 to 4 weeks.

37. (Amended) A method according to ~~any one of claims~~ claim 1-28, wherein said compound is administered at least daily for 3 to 7 days every 2 to 5 weeks.


38. (Amended) A method according to ~~any one of claims~~ claim 1-28, wherein said compound is administered at least daily 4 to 6 days every 2 to 5 weeks.

44. (Amended) A method according to ~~any one of claims~~ claim 1-28, wherein the compound is of the formulas






45. (Amended) A method according to any one of claims claim 1 to 28, wherein the compound is of the formula



46. (Amended) A method according to any one of claims claim 1 to 28, wherein the compound is of the formula



46 47. (Amended) A method according to ~~any one of claims~~ claim 1 to 28, wherein the compound is selected from

4-HEXYL-BENZOIC ACID 4-(4-AMINO-2-OXO-2H-PYRIMIDIN-1-YL)-
[1,3]DIOXOLAN-2-YLMETHYL ESTER (~~No.~~ 191);

8-PHENYL-OCTANOIC ACID [1-(2-HYDROXYMETHYL-[1,3]DIOXOLAN-4-YL)-
2-OXO-1,2-DIHYDRO-PYRIMIDIN-4-YL]-AMIDE (~~No.~~ 197);

8-PHENYL-OCTANOIC ACID 4-(4-AMINO-2-OXO-2H-PYRIMIDIN-1-YL)-[1,3]
DIOXOLAN-2-YLMETHYL ESTER (~~No.~~ 198);

4-PENTYL-BICYCLO[2.2.2]OCTANE-1-CARBOXYLIC ACID 4-(4-AMINO-2-OXO-
2H-PYRIMIDIN-1-YL)-[1,3]DIOXOLAN-2-YLMETHYL ESTER (~~No.~~ 211);

4-PENTYL-CYCLOHEXANECARBOXYLIC ACID 4-(4-AMINO-2-OXO-2H-
PYRIMIDIN-1-YL)-[1,3]DIOXOLAN-2-YLMETHYL ESTER; (~~No.~~ 240)

or mixtures thereof.

2025 RELEASE UNDER E.O. 14176